id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-262188-a20vb800	Horisberger, Alice	Impact of COVID-19 pandemic on SLE: beyond the risk of infection	2020-05-05		.txt	text/plain	1107	75	49	One may hypothesise that the increased bioavailability of type 1 IFN in SLE promotes host defenses against SARS-CoV2 infection and provide some degree of protection against severe COVID-19 in this patient population. Given their antiviral effect against SARS-CoV-2 in vitro, antimalarials (hydroxychloroquine and chloroquine) represent a potential adjunct treatment for patients with COVID-19 infection. Small uncontrolled or poorly controlled clinical trials have shown an antiviral effect of antimalarials in COVID19 Lupus Science & Medicine contributing to the growing interest of the health authorities, media and general population. Since only limited data support the use of these drugs in COVID-19, a recent document emphasised the importance of limiting their systematic use in COVID-19 and rationing the supply available for clinical trials and for patients with SLE or with other rheumatic diseases. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients	./cache/cord-262188-a20vb800.txt	./txt/cord-262188-a20vb800.txt